Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen accrued Product Sales Returns Liability (legacy standalone disclosure) ($M) ($M)
Form 10-K Summary of Significant Accounting Policies (XBRL)
Latest, Q4 2022
548
Period ended Dec 31, 2022
Change on a year earlier
+1.1%
542 in Q4 2021
History
8 quarters
Since Q4 2015
Sources
6
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accrued Product Sales Returns Liability (legacy standalone disclosure) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2022 | Dec 31, 2022 | 548 | +1.1% | Form 10-K (filed 2023-02-09) ↗ |
| Q4 2021 | Dec 31, 2021 | 542 | +14.3% | Form 10-K (filed 2023-02-09) ↗ |
| Q4 2020 | Dec 31, 2020 | 474 | -16.0% | Form 10-K (filed 2022-02-16) ↗ |
| Q4 2019 | Dec 31, 2019 | 564 | +5.4% | Form 10-K (filed 2021-02-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 535 | +17.6% | Form 10-K (filed 2019-02-13) ↗ |
| Q4 2017 | Dec 31, 2017 | 455 | +4.1% | Form 10-K (filed 2019-02-13) ↗ |
| Q4 2016 | Dec 31, 2016 | 437 | +12.1% | Form 10-K (filed 2018-02-13) ↗ |
| Q4 2015 | Dec 31, 2015 | 390 | – | Form 10-K (filed 2017-02-14) ↗ |
Cite this data
StockData. (2026). Amgen Accrued Product Sales Returns Liability (legacy standalone disclosure) ($M) ($M), quarterly Q4 2015–Q4 2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gtn_returns_liab
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.